Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Brain Res ; 1603: 141-9, 2015 Apr 07.
Article in English | MEDLINE | ID: mdl-25662771

ABSTRACT

Our previous findings indicated that in rats subjected to subarachnoid hemorrhage (SAH), suppression of post-SAH neuroinflammation via vascular adhesion protein-1 (VAP-1) blockade provides significant neuroprotection. We and others have reported that neuroinflammation contributes to cerebral microvascular impairment. Thus, in the present study, we tested the hypotheses that: (1) treatment with LJP-1586, a selective VAP-1 blocker, prevents SAH-associated pial arteriolar dilating dysfunction; and (2) the vasculoprotective effect of LJP-1586 arises from inhibiting SAH-elicited neutrophil recruitment. We utilized an endovascular perforation model of SAH. Rats subjected to SAH were either treated with LJP-1586 or rendered neutropenic via anti-neutrophil-antibody treatment. Findings from these groups were compared to their respective control groups. At 48 h post-SAH, rats were evaluated for neurobehavioral function, pial venular leukocyte trafficking, and pial arteriolar reactivity to topically-applied acetylcholine (ACh) and S-nitroso-N-acetyl penicillamine (SNAP). Pial arteriolar responses decreased at 48 h post-SAH. However, in the presence of LJP-1586, those responses were significantly preserved. Neutrophil-depletion yielded a substantial suppression of SAH-associated leukocyte adhesion and infiltration. This was accompanied by a significant preservation of pial arteriolar dilating function, suggesting a direct link between neutrophil recruitment and the loss of cerebral microvascular reactivity. Moreover, neutrophil depletion also was associated with significant protection of neurobehavioral function. The present findings suggest that attenuating SAH-linked elevation in neutrophil trafficking will protect against the development of microvascular dysfunction and subsequent neurological impairment.


Subject(s)
Allylamine/analogs & derivatives , Amine Oxidase (Copper-Containing)/antagonists & inhibitors , Cardiovascular Agents/pharmacology , Cell Adhesion Molecules/antagonists & inhibitors , Neutrophil Infiltration/drug effects , Subarachnoid Hemorrhage/drug therapy , Acetylcholine/pharmacology , Allylamine/pharmacology , Amine Oxidase (Copper-Containing)/metabolism , Animals , Arterioles/drug effects , Arterioles/physiopathology , Cell Adhesion Molecules/metabolism , Cerebrovascular Circulation/drug effects , Cerebrovascular Circulation/physiology , Cholinergic Agonists/pharmacology , Disease Models, Animal , Leukocytes/drug effects , Leukocytes/physiology , Male , Neuroimmunomodulation/drug effects , Neuroimmunomodulation/physiology , Neutrophil Infiltration/physiology , Neutrophils/drug effects , Neutrophils/physiology , Nitric Oxide Donors/pharmacology , Pia Mater/blood supply , Pia Mater/drug effects , Pia Mater/physiopathology , Rats, Sprague-Dawley , Regional Blood Flow/drug effects , Regional Blood Flow/physiology , S-Nitroso-N-Acetylpenicillamine/pharmacology , Subarachnoid Hemorrhage/mortality , Subarachnoid Hemorrhage/physiopathology , Venules/drug effects , Venules/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...